Interim report May – Jan 2022/23: Solid growth and stronger market presence
The period Nov 1st 2022 – Jan 31st 2023 ▪ Net sales amounted TSEK 18 680 (12 636), which is an increase of 48% compared with the corresponding period last year. The growth in the US market is 40% compared with the corresponding period last year. ▪ Operating loss amounted to TSEK -13 773 (503) ▪ Net profit amounted to TSEK -14 176 (541) ▪ Cashflow from operating activities amounted to TSEK -14 083 (863) ▪ Earnings per share amounted to -0,74 SEK (0,03) Significant events in the quarter ▪ Continue to add well renowned hospitals, where NYU Langone, ranked